Analyst Coverage

Adial Pharmaceutical, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Adial Pharmaceutical, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Adial Pharmaceutical, Inc. or its management. Adial Pharmaceutical, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.